New ‘Dimension’ expands the gene therapy pipeline for Regenxbio – BioWorld Online
|
New 'Dimension' expands the gene therapy pipeline for Regenxbio
BioWorld Online The deal, which values Dimension at less than $100 million, adds gene therapy candidates DTX-301 for ornithine transcarbamylase (OTC) deficiency and DTX-401 for glycogen storage disease type Ia (GSDIa) to Regenxbio's metabolic disease franchise, … |
